| 0.7582 -0.012 (-1.53%) | 11-07 10:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.04 | 1-year : | 1.15 |
| Resists | First : | 0.89 | Second : | 0.99 |
| Pivot price | 0.83 |
|||
| Supports | First : | 0.74 | Second : | 0.62 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.83 |
| MA(100) : | 1.03 |
MA(250) : | 1.38 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 16 |
| RSI | RSI(14): 41 | |||
| 52-week | High : | 2.3 | Low : | 0.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LGVN ] has closed above bottom band by 17.3%. Bollinger Bands are 46.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.8 - 0.8 | 0.8 - 0.81 |
| Low: | 0.75 - 0.76 | 0.76 - 0.76 |
| Close: | 0.76 - 0.77 | 0.77 - 0.78 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Thu, 06 Nov 2025
Longeveron Inc. (NASDAQ:LGVN) Q3 2025 Earnings Call Transcript - Insider Monkey
Wed, 05 Nov 2025
Longeveron Inc. Reports Q3 2025 Financial Results - The Globe and Mail
Mon, 03 Nov 2025
Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2025 Result - Yahoo Finance
Tue, 28 Oct 2025
Longeveron (NASDAQ: LGVN) sets earnings call for Nov. 4 at 4:30 p.m. ET with webcast - Stock Titan
Wed, 01 Oct 2025
$1B Healthcare Deal Maker and St. Louis Cardinals Team Doctor Joins Longeveron's Board for Stem Cell Push - Stock Titan
Wed, 03 Sep 2025
Longeveron® Announces Key Leadership Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.135e+007 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 1,080 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.835e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 707.9 % |
| Return on Equity (ttm) | -67.5 % |
| Qtrly Rev. Growth | 2.07e+006 % |
| Gross Profit (p.s.) | -216.67 |
| Sales Per Share | -896.8 |
| EBITDA (p.s.) | 1.08667e+007 |
| Qtrly Earnings Growth | 0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.13 |
| Dividend | 0 |
| Forward Dividend | 1.26e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|